Skip to main content

A prostate cancer clinical trial - PR24

Testing two different radiation therapy strategies given with hormone therapy in patients at risk of recurrence of prostate cancer
Disease Site
Genito-Urinary Clinical Trials
Trial Code
PR.24 ǀ NCT06235697
Trial Status
Open to patient enrollment

What is the purpose of this study?

The purpose of this study is to compare the effects on you and your prostate cancer of getting a higher dose of radiation therapy given over a shorter period of time compared to the current way radiation therapy is used to treat prostate cancer.

Why is this study important?

Some research suggests that receiving higher doses of radiation therapy over a shorter period of time may work just as well in controlling your prostate cancer. Benefits of the new strategy may include fewer clinic visits, better quality of life, and decreased costs over time for the Health Care System. However, it is not clear if this approach offers better control of the cancer compared to standard treatment or results in fewer side effects.

Who can participate in this study?

This trial is for:

  • People diagnosed with prostate cancer that has not spread to other organs in the body but is at risk of eventually spreading

This trial is not for:

  • People who have had prior surgery, chemotherapy, or radiation therapy to treat their prostate cancer
  • People who are not judged medically fit to receive hormone therapy or radiation therapy
What are the risks?
  • If you choose to take part in this study, there is a risk that the high dose radiation therapy approach with fewer treatment sessions may not be as good as the usual approach for preventing your cancer from spreading. There is also a risk that you could have more side effects from this treatment approach.
  • Some of the most common side effects that the study doctors know about are:
    - Tiredness
    - Skin changes (redness, peeling, irritation
    - Bowel Changes such as rectal irritation, diarrhea, constipation
    - Bladder changes such as frequent urination, pain, difficulty emptying the bladder or urinating
  • You will find more details about the side effect risks in the longer “informed consent” document you will review with your health care team. 
What can I expect?
  • If you choose to take part in this study, you will be randomly placed in one of two groups and you will receive either the higher dose radiation therapy over a shorter period of time or the radiation therapy on the standard schedule commonly used to treat patients like you.
  • Regardless of the group you are in, you will receive hormone therapy (also known as androgen deprivation therapy), which is known to help make radiation therapy more effective in treating your cancer.
  • In this study, you will also be asked to complete a few questionnaires at different times, to understand your Quality of Life. 

How can I find out more or join the study?

Talk to your healthcare providers if you are considering joining this study. You can share summaries like this with them and ask if they think joining the trial may be a good option for you.

Before you join this study, you will be asked to review an Informed Consent document, which will tell you more about why the research is being done and your role as a participant. You will have an opportunity to discuss anything that is not clear and ask any questions you have.

Joining this study is entirely up to you and you can decide to leave at any time without giving a reason. Your decision to join or leave the trial will not affect your medical care.

The CCTG-PR24 study is currently enrolling patients at a variety of sites in Canada and the USA. For a full list of participating cancer centres and more information about the study, please visit online www.clinicaltrials.gov and search using the keyword “NCT06235697”.

Use this trial information for your conversation with your health care team

Participating centres
  • The Jewish General Hospital - Montreal, QC, H3T 1E2 - Contact: Dr. M. Tamim Niazi
  • Odette Cancer Centre Sunnybrook Health Sciences Centre - Toronto, ON, M4N 3M5 - Contact: Dr. Douglas Andrew Loblaw
  • University Health Network Princess Margaret Cancer Centre - Toronto, ON, M5G 2M9 - Contact: Dr. Rachel Mara Glicksman
  • Trillium Health Partners - Credit Valley Hospital - Mississauga, ON, L5M 2N1 - Contact: Dr. Jasper Yuen